HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a 'Buy' rating on Rani Therapeutics Hldgs (NASDAQ:RANI) and maintained a $20 price target.
September 20, 2023 | 10:39 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rani Therapeutics Hldgs (NASDAQ:RANI) has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $20.
The reiteration of a 'Buy' rating and maintenance of a $20 price target by HC Wainwright & Co. indicates a positive outlook for Rani Therapeutics Hldgs. This could potentially lead to an increase in investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100